Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. Tol J, et al. Among authors: mol l. Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272912 Free article. Clinical Trial.
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ. Koopman M, et al. Among authors: mol l. Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1. Lancet. 2007. PMID: 17630036 Clinical Trial.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Tol J, et al. Among authors: mol l. N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. N Engl J Med. 2009. PMID: 19196673 Free article. Clinical Trial.
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy.
van Iersel LBJ, Koopman M, van de Velde CJH, Mol L, van Persijn van Meerten EL, Hartgrink HH, Kuppen PJK, Vahrmeijer AL, Nortier JWR, Tollenaar RAEM, Punt C, Gelderblom H. van Iersel LBJ, et al. Among authors: mol l. Ann Oncol. 2010 Aug;21(8):1662-1667. doi: 10.1093/annonc/mdp589. Epub 2010 Jan 28. Ann Oncol. 2010. PMID: 20110289 Free article. Clinical Trial.
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, Mol L, Vincent AD, Teerenstra S, Punt CJ. Knijn N, et al. Among authors: mol l. Eur J Cancer. 2011 Feb;47(3):369-74. doi: 10.1016/j.ejca.2010.10.006. Epub 2010 Nov 8. Eur J Cancer. 2011. PMID: 21067912 Clinical Trial.
Bevacizumab and cancer treatment-related mortality.
Punt CJ, Mol L, Koopman M. Punt CJ, et al. Among authors: mol l. JAMA. 2011 Jun 8;305(22):2292; author reply 2292-3. doi: 10.1001/jama.2011.758. JAMA. 2011. PMID: 21642679 No abstract available.
71 results